-
VivaVision Biotech Inc. Receives FDA Approval for VVN461 Phase II Clinical Trial
•
China’s VivaVision Biotech Inc. has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase II clinical trial for its in-house developed drug candidate, VVN461. The trial will assess the efficacy of VVN461 as a treatment for inflammation following cataract surgery. VVN461’s…
